Team
Meet the Team
David Longo
Chief Executive Officer
Chief Executive Officer
David Longo is the Co-Founder and Chief Executive Officer (CEO) of Ordaōs. As CEO of Ordaōs, Longo leads a strong scientific team to design novel mini-proteins that help drug hunters deliver safer and more effective treatments.
Longo brings to Ordaōs, broad experience in innovation and technology, that compel him to approach protein design in a unique way. His expertise in AI and machine learning is incorporated into Ordaōs’ Design Engine, driving the rapid creation of never-before-seen mini-proteins with improved probability of more therapeutically effective candidates. Prior to Ordaōs, this entrepreneur led a series of companies which he grew into successful entities.
Longo has an MS in biotechnology from Harvard University, graduate certificates in AI, Machine Learning, Innovation and Technology from Stanford University and Massachusetts Institute of Technology (MIT), and a master’s Certificate in Music Production from Berklee College of Music. He has a Bachelor of Science in Computational Mathematics from Rochester Institute of Technology. David is a learner, triathlete, and an inspirational leader.
Matthias Denecke
Chief Technology Officer
Chief Technology Officer
Matthias Denecke, PHD, is the Senior Vice President of Engineering at Ordaōs, where he is responsible for the design, implementation and deployment of deep learning technologies for protein generation. Dr. Denecke brings to Ordaōs extensive experience in machine learning, artificial intelligence, and natural language processing. He has advanced expertise in programming and applications as well as identifying, isolating, and resolving technical issues. He is skilled in multiple programming languages and in the ability to build and strengthen relationships across functions to drive cohesive strategic operations. He holds two patents, has several publications, and has conducted a variety of technical projects for major firms including Ford, Deloitte and Pfizer, and research projects for Army Research Lab, ADELPHI, Defense Advanced Research Projects Agency (DARPA) and BOSCH.
Prior to Ordaōs, Dr. Denecke was the Chief Technology Officer for Qeep (qeep.ai) where he built interactive technical documentation with AI-supported conversational interfaces to help engineers work more productively and reduce human errors. Before that, Dr. Denecke was the Co-Founder of Agilingua where he developed interactive spoken language applications based on their proprietary ATOM Dialogue Engine which was used in in-car infotainment systems, interactive electronic manuals, human-robot interactions, and computer-assisted language learning.
Dr. Denecke received his PHD in Rapid Prototyping of Spoken Dialogue Systems from the University of Karlsruhe. He earned a diploma in Computational Linguistics from the University of Stuttgart and a diploma in Computer Science at the University of Karlsruhe.
Victor Bustos
VP of Pre-clinical R&D
Steve Haber
Chief Solutions Architect
Jacob Tourjeman
SVP of Operations
Sasen Efrem
Senior Scientist
Jeff LaFrence
Senior Bioprocess Engineer
Beth Rosocha
VP of Project and Portfolio Management
John Janczy
Principal Scientist
Daniel Cohen
Principal Scientist
Max Bluestone
Senior AI Lead
Luke Martin
Senior AI Scientist
Sahil Arora
Senior AI Scientist
Robyn Dopke
Operations I
Lahari Gorantla
Computational Biologist II
Alexandru Stirbu
Senior AI Scientist
Shane Murray
Platform Lead
Howard Shelburne
Senior Full Stack Developer
Chris Reed-Asakawa
Senior Full Stack Developer
Furkan Aksoy
Platform Engineer I
Obeyda Djeffal
Senior DevOps Engineer
Alena Romanova
Scientist I
Jonas Schemm
Associate Scientist
Jasmine Choi
Lab Manager I
At Ordaos Bio, we are working towards a paradigm shift within our industry, and we need top talent to play an integral role in changing the future of medical research as we know it.
All full-time roles are eligible for benefits and additional perks including commuter benefits, continuing education reimbursement, extended parent and family leave, floating holidays, and more.